Inspire Medical Systems, Inc. (INSP) stock
INSPNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3057% below fair value
$59.41+0.29 (+0.49%)
Close on Nov 17, 2026Market cap $1.72BP/E 12.9Yield –
Inspire Medical Systems r&d expenses
Research and development expenses are spending on new products and technology.
Inspire Medical Systems's R&D Expenses for the twelve months ending Jun 30, 2026 was $99.68M, down 9.7% year over year. For fiscal 2025 it was $103.17M, down 9.6% from the year before. The highest annual figure on record is $116.54M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.17M | -9.6% |
| FY2024 | Dec 31, 2024 | $114.13M | -2.1% |
| FY2023 | Dec 31, 2023 | $116.54M | +69.8% |
| FY2022 | Dec 31, 2022 | $68.65M | +83.8% |
| FY2021 | Dec 31, 2021 | $37.35M | +43.1% |
| FY2020 | Dec 31, 2020 | $26.09M | +103.2% |
| FY2019 | Dec 31, 2019 | $12.84M | +73.8% |
| FY2018 | Dec 31, 2018 | $7.39M | +19.3% |
| FY2017 | Dec 31, 2017 | $6.19M | -12.6% |
| FY2016 | Dec 31, 2016 | $7.09M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $24.70M | -5.8% |
| Q1 FY2026 | Mar 31, 2026 | $25.83M | -7.1% |
| Q4 FY2025 | Dec 31, 2025 | $24.94M | -17.8% |
| Q3 FY2025 | Sep 30, 2025 | $24.21M | -7.2% |
| Q2 FY2025 | Jun 30, 2025 | $26.21M | -9.2% |
| Q1 FY2025 | Mar 31, 2025 | $27.80M | -3.6% |
| Q4 FY2024 | Dec 31, 2024 | $30.34M | -2.3% |
| Q3 FY2024 | Sep 30, 2024 | $26.08M | -10.5% |
| Q2 FY2024 | Jun 30, 2024 | $28.86M | -6.4% |
| Q1 FY2024 | Mar 31, 2024 | $28.85M | +13.1% |
| Q4 FY2023 | Dec 31, 2023 | $31.05M | +46.1% |
| Q3 FY2023 | Sep 30, 2023 | $29.14M | +38.8% |
| Q2 FY2023 | Jun 30, 2023 | $30.82M | +112.1% |
| Q1 FY2023 | Mar 31, 2023 | $25.52M | +115.0% |
| Q4 FY2022 | Dec 31, 2022 | $21.25M | +106.4% |
| Q3 FY2022 | Sep 30, 2022 | $20.99M | +118.4% |
| Q2 FY2022 | Jun 30, 2022 | $14.53M | +56.5% |
| Q1 FY2022 | Mar 31, 2022 | $11.87M | +45.6% |
| Q4 FY2021 | Dec 31, 2021 | $10.29M | +41.3% |
| Q3 FY2021 | Sep 30, 2021 | $9.61M | +31.6% |
| Q2 FY2021 | Jun 30, 2021 | $9.29M | +53.2% |
| Q1 FY2021 | Mar 31, 2021 | $8.15M | +49.9% |
| Q4 FY2020 | Dec 31, 2020 | $7.29M | +93.4% |
| Q3 FY2020 | Sep 30, 2020 | $7.31M | +101.7% |
| Q2 FY2020 | Jun 30, 2020 | $6.06M | +113.0% |
| Q1 FY2020 | Mar 31, 2020 | $5.44M | +108.9% |
| Q4 FY2019 | Dec 31, 2019 | $3.77M | +75.0% |
| Q3 FY2019 | Sep 30, 2019 | $3.62M | +104.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.85M | +64.0% |
| Q1 FY2019 | Mar 31, 2019 | $2.60M | +50.5% |
| Q4 FY2018 | Dec 31, 2018 | $2.15M | +27.9% |
| Q3 FY2018 | Sep 30, 2018 | $1.77M | +50.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.74M | -0.5% |
| Q1 FY2018 | Mar 31, 2018 | $1.73M | +8.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.68M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.18M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.74M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.59M | – |
See a number that looks wrong?